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establishing now in Ukraine. Methods: We performed a retrospective analy-
sis of the real data from 450 medical records of patients who were treated 
in a Lviv Regional Perinatal Center in 2013. The results of our previous study of 
treatment cost of endometriosis in Ukraine were used (Zalis’ka O., Piniazhko O. 
et al. 2014). We used the prices from Ukrainian database of Morion company 
(Kiev) on 01.06.2014 (1 EUR = 16,04 UAH). Results: According to the analysis 
70% of women with endometriosis choose treatment hormones with the dura-
tion of six month usually and 30% of patients undergo surgical treatment. 
Annual direct cost of endometriosis per patient varies from € 224 to € 487 depending 
on the chosen scheme of pharmacotherapy, which differences 2 times. Accordingly, 
costs correlated with clinical severity and patient’s financial position and ability to 
pay. Based on the data of State Statistics Service of Ukraine, we estimated that the 
number of women of reproductive age in Ukraine was 14,7 million in 2013. Therefore 
when to extrapolate data the number of women with endometriosis could amount 
approximately 1,47 million and 1,03 million women would take pharmacotherapy 
instead of surgery. The annual cost of treatment hormones of endometriosis could 
amount from € 230,5 million to € 501,6 million. ConClusions: The economic burden 
of endometriosis in Ukraine demonstrates a significant need in the optimization of 
the management of this disease within the introduction of health insurance system 
and health technology assessment of the applicable hormones.
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objeCtives: Life expectancy in Italy is constantly increasing (+2,4 years for men and 
+1,7 years for women from 2001 to 2011) with a consequent effect on health needs 
and expenditure. Furthermore, on overall population, 21% has one chronic disease, 
9,3% two and 8% more than three. The aim of this study is to evaluate the burden 
of multiple chronic diseases and associated costs in a large community setting 
of Italian elderly population, starting from Cineca ARNO Observatory. Methods: 
ARNO Observatory is a comprehensive population-based database which integrates 
since 1987 administrative data from Local Health Units to monitor health data 
in the real world. On a population of 10,5 millions of inhabitants we selected a 
cohort of 2.166.000 (21%) subjects over 65 years. Outpatient drug prescriptions, inpa-
tient hospital discharges, diagnostic, lab tests prescriptions were analyzed during 
2012 to evaluate chronic diseases, multiple chronic conditions and illness direct 
costs. Results: From selected cohort, 82,5% has at least one chronic disease and 
this proportion rises up to 89,6% in over 80s. Hypertension is the most common 
disease (67%), followed by dyslipidemia (30%) and diabetes (18%). Over 50% of elderly 
has multiple chronic diseases but the risk of developing concomitant chronic ill-
nesses rises with ages (60% of people aged > = 85 have comorbidities). Integration 
of administrative data led to the evaluation of cost of illness which varies from 
2.528€ for hypertension to 13.613€ for Acute Coronary Syndrome; the average cost of 
patients with 2 or more comorbidities is twice than patients with only one chronic 
disease. In general, more than a half of cost is due to hospitalization (57%), 27% to 
drugs and 16% to diagnostic exams (16%). ConClusions: Analyses of real world 
data represent an effective tool for the evaluation of elderly population diseases 
and can be a valid instrument to support clinical governance.
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objeCtives: Preterm Labor (PTL) in pregnant women is a common obstetrics inpa-
tient diagnosis. It is important to differentiate between threatened PTL associated 
with potentially avoidable hospitalization and PTL resulting in a preterm birth (PTB) 
with respect to their burden to the health care system. The prevention and diag-
nostic-driven reduction of such hospital admissions for observational reasons are 
supposed to reduce costs. The aim is to analyze the epidemiological and financial 
impact of programs to prevent avoidable hospital admissions due to threatened 
PTL. Methods: A cohort of singletons at the University hospital Greifswald with 
PTL-related hospital admissions prior to birth was analyzed with respect to resource 
use and obstetrics outcomes. This bottom-up analysis was conducted from the 
perspective of the statutory health care system based on accounting information 
claims from the hospital`s database for the period 2007 to 2012. ICD-10 codes were 
used to identify the study population. All costs were inflated to 2012 using the 
German GDP index. Results: Out of 4,408 singleton births, potentially avoidable 
hospital admissions were found in 248 cases (5.6 %). In this subgroup, 17 infants 
were delivered preterm (avg. 34.8 weeks), resulting in a PTB rate of 6.9 % compared 
to a general rate of 8.7 % in Germany. These hospitalizations led to average costs of 
about 1,600 EUR per case (min. 300 EUR; max. 5,600 EUR). ConClusions: Although 
threatened PTL affects one singleton pregnancy in 20, the fraction of costs result-
ing from observational admissions associated with threatened PTL is less than 0.7 
percent compared to the total department costs. This finding conflicts with the 
cost-saving potential of prevention programs (e. g. pH self-assessment) suggested 
in the literature.
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between 2001 and 2012. One study was on early screening using maternal markers, 
and concluded that this may be cost-effective from a payer perspective. Three other 
studies focused on treatment and management, and concluded that induction of 
delivery is the most cost-effective option in term preeclampsia. Also, magnesium 
sulphate was found to be a cost-effective treatment, but more so in low income 
countries. One study was a comprehensive HTA report on combination strategies 
of screening and prevention, which found that providing calcium to all pregnant 
women without prior testing was the most cost-effective strategy. The BIA, on intro-
ducing a novel diagnostic test, concluded that the savings associated with this test 
would offset its initial cost. ConClusions: Novel biomarkers in screening for and 
diagnosing preeclampsia show promise as a cost-effective approach, from a payer 
perspective. Moreover, magnesium sulphate seemed to be a cost-effective option 
to manage seizures in preeclamptic women while delivery remains the ultimate 
efficient treatment, especially for women with term preeclampsia.
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objeCtives: To determine and quantify the level of price variation in inpatient care 
for obstetrical services across hospitals in the State of Vermont, USA. Methods: 
We used data from Vermont Healthcare Claims Uniform Reporting and Evaluation 
System (VHCURES) for the calendar year 2012. We generated single-line summaries 
for all inpatient obstetrical services with an admission date in 2012. We excluded 
records for Medicaid, secondary payments either to Medicare or another commer-
cial insurance, denied claims, non-VT resident claims and adjustments to existing 
claims. This produced a total of 4,019 records for the evaluated services from 13 
Vermont hospitals. We calculated the allowed amount for each Diagnosis Related 
Group (DRG) (total amount a hospital received from a payer, including any prepaid 
amounts related to the service, plus the amount due from a patient through copay-
ment, co-insurance and deductible). The outcome of interest is the average price 
of a specific DRG at each hospital as a percent of group average price in Vermont 
Hospitals. To reflect patient severity we adjusted prices by case-mix. Results were 
generated for hospitals only when there were at least 10 discharges in a specific 
hospital. Results: The average prices for a vaginal delivery with complicating diag-
noses varied between 66% to 156% of the group average, vaginal delivery without 
complicating diagnoses varied between 74% to 182%, neonate with other significant 
problems varied between 60% to 206% and normal newborn varied between 77% to 
180%. ConClusions: There is wide variation in payments for obstetrical services 
across Vermont hospitals. Further analysis is necessary to understand the role of 
various factors that contribute to this variation. During this transition period to a 
single-payer system in the rural state of Vermont, policy makers will need evidence-
based information to ensure undiminished access to care in obstetrical services.
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objeCtives: To estimate the economic impact of malnutrition on annual direct 
cost in Spanish institutionalized or community-dwelling older adults. Methods: 
A systematic review was carried out on the economic burden and use of medi-
cal resources associated with malnutrition in institutionalized or community-
dwelling older adults. National and international databases until December 2013 
were searched. Based on results from the literature review, an Excel-based tool 
was developed to estimate the annual cost difference between malnourished and 
well-nourished institutionalized and community-dwelling older adults in Spain. 
Malnutrition prevalence, annual frequency of general practitioner (GP) visits and 
hospitalizations were the main inputs considered in the model. Unit costs were 
derived from health care cost databases available in Spain (Euros, 2014). One-way 
sensitivity analysis (OWSA) was performed. Results: The results of the systematic 
review showed that malnutrition implies higher medical costs in the study popula-
tion, particularly due to the length of hospital stay, number of hospital admissions 
and GP visits. Economic results showed that the annual cost associated with the 
use of resources of a malnourished patient (€ 5,000.66) was 3.5 times higher than 
that of a well-nourished (€ 1,433.78). OWSA showed that prevalence of malnutrition 
was the variable with the greatest impact on results. Decreasing the prevalence 
of malnutrition according to minimum values identified in the literature (from 
15.6% and 4.4%, to 2% and 3% in institutionalized and community-dwelling patients 
respectively), caused the annual cost per patient with malnutrition to drop from 
€ 5,000.66 to € 2,511.83, while increasing it to the maximum values (62% and 23%, 
respectively), implied a rise from € 5,000.66 to € 24,291.93 in the annual cost per 
patient. ConClusions: Adopting measures to reduce the prevalence of malnu-
trition in institutionalized or community-dwelling older adults would reduce by 
up to 50% the annual cost per patient associated to GP visits and hospitalizations.
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objeCtives: Endometriosis affects 10% of women of reproductive age and WERF 
EndoCost study has recently shown that it imposes substantial economic burden 
on society through the reduced economic and personal productivity. The aim of 
the study was to estimate the prevalence of endometriosis and the cost of ill-
ness from the payer’s perspective in Ukraine as the model of health insurance is 
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objeCtives: Cost is considered one of the major barriers to greater use of LARC 
(Long-Acting Reversible Contraceptive) methods, especially cost of treatment initia-
tion. However, when considering their contraceptive efficacy alongside cost of preg-
nancy, LARC methods are deemed by NICE to be more cost-effective than combined 
oral contraceptive pills even at one year of use. (NICE LARC CG30 2005). Methods: 
A 3 year time-horizon cost-benefit model was developed to assess budgetary impact 
of increasing LARC uptake (implant, IUD, IUS and injectable) compared to the oral 
contraceptive pill, in UK women aged 16-49 who currently use the following con-
traceptives of interest: non-LARC method (defined as contraceptive pill only) or 
LARC methods (IUD, IUS, injectable, implant). A weighted-average price based on 
current market shares was calculated, for all contraceptive pills currently available 
in the UK. Increased uptake of any LARC method was offset against a reduction in 
contraceptive pill usage. Unintended pregnancies, based on typical failure rate, 
occurring with all treatments considered was taken into account. Results: Of 
approximately 14,750,000 women aged 16-49 in the UK, official statistics confirm 
37% use contraceptive methods of interest to our model. This proportion formed 
our cohort of approximately 5,500,000 UK women aged 16-49, which was followed 
over a 3 year time horizon. A 100% increase in uptake of each LARC method would 
lead to a 49% decrease in oral contraceptive pill uptake. Over a three year period 
this would save 374,794 unintended pregnancies, and elicit financial savings of 
£630,831,022, on which £54,098,847 is attributable to treatment costs (ingredient, 
consultations, removal/insertion costs) and £576,732,175 to the cost of unintended 
pregnancies (live birth, miscarriage, abortion, ectopic pregnancy). ConClusions: 
The model projects that increasing LARC uptake will result in a significant reduc-
tion in the number of unintended pregnancies, with consequent savings to the 
NHS across the UK.
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objeCtives: Our aim was to assess the costs and consequences of labour induction 
using misoprostol vaginal insert (MVI) compared with currently used technologies 
using a specifically developed user-friendly decision model developed for Austria, 
Poland, Romania, Russia and Slovakia. Methods: The model was developed in 
Microsoft Office Excel and compares clinical and safety aspects like time to vaginal 
delivery, time to active labour, occurrence of cesarean delivery and adverse events 
of MVI with selected comparators. Efficacy and safety data were retrieved from tar-
geted literature review, conducted in the main medical databases. Country-specific 
information about costs and resource use was incorporated into the model. Local 
data were collected for each country via a specifically developed questionnaire. The 
model considered the hospital and public payer perspectives. The model gener-
ated results as an incremental difference between the total costs related to labour 
induction with MVI or a comparator. The threshold price of MVI was also calcu-
lated. Results: Local Key Opinion Leaders recommended the following compara-
tors: dinoprostone vaginal insert (DVI; Austria), dinoprostone vaginal tablets (Dtab; 
Austria, Slovakia), dinoprostone cervical gel (Dgel; Poland, Russia, Slovakia) and 
oxytocin (Austria, Poland, Romania, Russia). The hospital perspective was chosen 
as default (additionally the public payer perspective was adopted for 2 countries). 
The use of MVI in most scenarios is related to a reduction in time consumption of 
hospital staff and in the length of patients’ stay in hospital wards. MVI was less 
costly or marginally more expensive in 80% of cases. ConClusions: Induction of 
labour with the use of MVI using a hospital perspective, brought savings in most 
countries and scenarios in comparison to other prostaglandins (DVI, Dtab, Dgel).
PIH25
Cost effeCtIveness analysIs of a vaCCInatIon PrograMMe for tHe 
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objeCtives: Herpes Zoster is a very painful and debilitating disease for which no 
satisfactory treatment exist. A vaccine is licensed in Europe for the prevention of 
Herpes Zoster (HZ) and postherpetic neuralgia (PHN) in adults aged ≥ 50 years and 
is recommended in France and UK. The objective of this study was to assess the 
cost-effectiveness of vaccination programs in people aged 65 years and over in 
Norway. Methods: An existing European Markov cohort Model was adapted to 
the Norwegian health care setting. Health states considered are healthy, HZ, PHN, 
healthy post-HZ and death. HZ and PHN states are further split by pain severity 
(mild, moderate or severe). A vaccine efficacy durability model based on the pivotal 
trial data was included to simulate waning in the efficacy. The cost-effectiveness 
outcomes were assessed from both the third party payer and the societal perspec-
tive. First, analysis comparing a HZ vaccination policy for adults aged ≥ 65 years with 
a no vaccination policy was done. Then, analysis comparing vaccination policies 
of 5-years age class cohorts (from 65 to 100 years old) to a no vaccination policy 
were conducted. Input data were obtained from Norwegian sources whenever avail-
objeCtives: Although the relationship between use of glucocorticoids (GC) and 
occurrence of adverse events (AE) is widely acknowledged, the estimation of risk 
size of specific AE is still imprecise. The aim of study was to quantify the incidence 
and economic cost of selected steroid-related AE in GC-users regardless of baseline 
chronic disease. Methods: Review of the available data about the consequences 
of long-term use of oral GC (depending on prednisone or its equivalent dose and 
period of use) was conducted. From 162 full-text publications (10024 abstracts), 
four with mixed population and > 5 years median follow–up were valuable. Hip 
fracture (HFr), cataract (CAT) and diabetes mellitus (DM) were chosen as the com-
mon and most cost generating AE connected with oral GC treatment. A Markov 
model with a lifetime horizon (30 years) was developed to forecast incidence 
and health care cost of three regimen (non-GC, low dose GC < 2.5 mg, high dose 
GC > 7.5 mg). Direct medical costs were included in the analysis. Results: For a 
lifetime horizon the incidence of HFr, CAT and DM increased from 0.77% to 5.49%, 
23.48% to 91.04% and 12.34% to 17.02% (7.1, 3.9, 1.4 fold increase) respectively for 
comparison non-GC versus high dose GC. For selected cohort of 1,000 you need to 
treat 34, 2, 22 patients respectively (low dose GC instead of high dose GC) to prevent 
one additional case of HFr, CAT, DM. Shorter duration of steroid therapy (5 years) 
provide two Quality-Adjusted Life Months gained (per one patient) and leads to 
2,230, 35,460, 6,920 avoided cases of HFr, CAT, DM (per 100,000 cohort). The use 
of low-dose or non-GC is cost-effective strategy (total cost per patient 2,958 PLN, 
1,301 PLN, respectively) compared with high-dose GC (10,823 PLN). ConClusions: 
Oral GC treatment can lead to dose-dependent increase in the risk of selected AE.
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objeCtives: Some drugs increase risk for adverse effects in elderly patients. 
Accordingly, lists of potentially inappropriate medication (PIM) that should be 
avoided in elderly patients have been proposed. In 2010 an expert panel published 
a PIM list adapted to the German drug market (PRISCUS-list) which lists 83 inappro-
priate agents and their recommended surrogates. This study calculates the amount 
of drug reimbursement of PIM and the potential saving using appropriate surrogates 
recommended by the PRISCUS list from the perspective of statutory health insur-
ance (SHI). Methods: Data was provided by AOK Research Institute (WIdO). Study 
material consists of a register extraction of the top 30 drugs (by sales) on PRISCUS-
list in 2009 for patients ≥ 65 years of the entire SHI-population. We calculated the 
percentage of sales and defined daily doses (DDD) for patients ≥ 65 compared to 
the total SHI-population. Costs for the recommended substitution were estimated 
by different scenarios. Results: In 2009, the proportion of the top 30 drugs on 
the PRISCUS-list that were prescribed to patients ≥ 65 was 58.2%. Sotalol was the 
drug with the largest proportion of DDD prescribed to patients ≥ 65 (92.9%). Drug 
reimbursement for the top 30 PIM medications prescribed to patients ≥ 65 were 
€ 305.7 million (54.3% of total reimbursement). Reimbursement for Solifenacin was 
highest with € 32.5 million. Prescription of the surrogates would lead to increasing 
costs for the German health care system. Those were calculated to range between 
€ 325.9 million and € 810.0 million. ConClusions: This is the first study assessing 
the economic burden of PIM according to PRISCUS-list in Germany. The results show 
that a more appropriate medication for the elderly comes along with additional 
costs. For a final evaluation of relevance and economics of PIM, costs of adverse 
drug events caused by PIM and clinical feasibility of substitution have to be taken 
into consideration.
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PreMenstrual syndroMe
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objeCtives: The primary objective of the study was the analysis of pharmaco-
economic expediency of administration of dydrogesterone (Duphaston®) for 
premenstrual syndrome (PMS) treatment in comparison with micronized pro-
gesterone (Utrogestan®). Methods: The mathematical modeling with dydroges-
terone or micronized progesterone was applied in the study. For the calculation 
of the efficacy data of clinical trials were used. Costs were calculated on the basis 
of Russian prices (grls. rosminzdrav. ru). The model was constructed as follow-
ing: for each branch of the decision tree, cost and efficacy for a group of 100 
patients (female aged 18 – 45 years) and per patient were analyzed. Modeling 
duration was 3 months (therapy during three cycles). The cost-effectiveness ratio 
(CER) and incremental cost-effectiveness ratio (ICERs) were calculated. Results 
were evaluated to cost-effectiveness threshold. Efficiency was estimated on 
the basis of clinical trials (effectiveness). Calculation of cost included: the cost 
of drugs administration course; costs of consultative and diagnostic appoint-
ments of the gynecologist; the cost of inefficient therapy – costs of additional 
diagnostic examination. The comprehensive sensitivity analysis was per-
formed. Results: The cost of the total course of therapy with dydrogesterone 
was more expensive in comparison with micronized progesterone – 84,1 EUR 
against 82,6 EUR. Strategy of administration of dydrogesterone showed more 
efficiency in comparison with micronized progesteron (8% increase of effective-
ness). CER for dydrogesterone and micronized progesterone were 115.20 and 
127.07 respectively. The ICER was 18.75 Eur per patient that is much lower than 
a cost-effectiveness threshold in Russia (27922.8 EUR). The sensitivity analysis 
confirmed conclusions of the main scenario. ConClusions: The strat-
egy of administration of dydrogesterone in PMS is economically expedient 
from the point of view of cost-effectiveness ratio. In addition, increase of effec-
tiveness was noted for use of dydrogesterone. The study was conducted at Abbott 
support.
